Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell Carcinoma

Small Cell Carcinoma Clinical Trial

Official title:

A Phase 1 Study of Weekly Paclitaxel and Nortriptyline for Relapsed Small Cell Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02881125
• Other study ID #: 9618
• Secondary ID: NCI-2016-0119796
• Status: Completed
• Phase: Phase 1
• Start date: November 3, 2016
• Est. completion date: November 30, 2019

Study information

• Verified date: December 2019
• Source: University of Washington
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I trial studies the side effects and best dose of nortriptyline hydrochloride when given together with paclitaxel in treating patients with small cell carcinoma that has come back. Nortriptyline hydrochloride, may help disrupt survival signals and cause cancer cell death. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nortriptyline hydrochloride and paclitaxel may work better in treating patients with small cell carcinoma.

Description:

PRIMARY OBJECTIVES:

I. To determine the maximally tolerated dose (MTD) of nortriptyline hydrochloride (nortriptyline) combined with weekly paclitaxel (PC).

SECONDARY OBJECTIVES:

I. To assess the overall response rate (ORR) to nortriptyline combined with PC.

II. To assess progression free survival (PFS) and overall survival (OS).

OUTLINE: This is a dose-escalation study of nortriptyline hydrochloride.

Patients receive paclitaxel intravenously (IV) on days 1, 8, and 15. Patients also receive nortriptyline hydrochloride orally (PO) once daily (QD) on days 1-7, twice daily (BID) on days 8-14, and thrice daily (TID) on days 15-28 of course 1 and TID on days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 28 days and every 3 months for 2 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2
• Est. completion date: November 30, 2019
• Est. primary completion date: January 1, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Ability to understand and the willingness to sign a written informed consent

• Pathologically-confirmed small cell carcinoma of any primary site

• Relapse following platinum-based chemotherapy or documented progressive disease while on platinum-based chemotherapy

• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 at time of informed consent

• Absolute neutrophil count >= 1.5 x 10^9 cells/L

• Hemoglobin (Hgb) >= 9.0 g/dL

• Platelets >= 100,000 x 10^9/L

• Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)

• Alkaline phosphatase levels =< 2.5 x upper limit of normal (ULN)

• Total bilirubin =< 1.5 x ULN

• Serum creatinine < 1.5 mg/dL

• At least one site of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria on computed tomography (CT) scan done within 30 days prior to study start

• Women of child-bearing potential and sexually active men must agree to use adequate contraception (hormonal, barrier method, or abstinence) prior to study entry, during treatment, and for three months after completing treatment

• Baseline electrocardiogram demonstrating all of the following: corrected QT (QTc) < 450 milliseconds (msec) (men) and < 470 msec (women), PR < 240 msec, QRS < 100 msec

Exclusion Criteria:

• Untreated active major depression

• Bipolar disorder

• Pregnancy and lactation; refusal to use adequate contraception

• History of seizures in the past 3 years

• Concurrent therapy with monoamine oxidase inhibitors (MAOI), selective serotonin reuptake inhibitors (SSRI), or other tricyclic antidepressants (TCA) or use within 2 weeks study start

• Concomitant therapy with any drugs shown to have major interactions with nortriptyline (i.e. known inhibitors of cytochrome P450 family 2 subfamily D member 6 [CYP2D6]) and use during the 30-day period prior to study start

• Myocardial infarction in preceding 4 weeks; history of uncontrolled cardiac arrhythmias or family history of sudden cardiac death

• Peripheral neuropathy grade 2 or greater

• Progressive or symptomatic central nervous system (CNS) metastases; patients with known brain metastasis must have stable disease following treatment surgery, radiation, or both

• Glaucoma

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Small Cell
• Small Cell Carcinoma
• Small Cell Lung Carcinoma

Intervention

Drug:
• Nortriptyline Hydrochloride
Given PO
• Paclitaxel
Given IV

Locations

Country	Name	City	State
United States	Fred Hutch/University of Washington Cancer Consortium	Seattle	Washington

Sponsors (2)

Lead Sponsor	Collaborator
University of Washington	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose, determined by the number of patients who experience a dose limiting toxicity	Maximum tolerated dose defined as the highest dose level of nortriptyline (in combination with weekly paclitaxel) where < 1/3 or < 2/6 patients experience a dose-limiting toxicity evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.	Up to 28 days
Secondary	Objective tumor response evaluated according to Response Evaluation Criteria in Solid Tumors version 1.1	Objective tumor response will be assessed with a 95% confidence interval.	Up to 2 years
Secondary	Overall Survival	Overall Survival will be described using Kaplan-Meier curves.	Up to 2 years
Secondary	Progression free survival	Progression free survival will be described using Kaplan-Meier curves.	Up to 2 years